Cancer
01 Jan 2013
Phase I/II Study of Concurrent Chemoradiotherapy for Newly-Diagnosed, Localized Nasal NK/T-Cell Lymphoma: Results of a Phase I Portion of JCOG0211-DI
Aim: To explore a more effective treatment for newly-diagnosed localized nasal NK/T-cell lymphoma, we conducted a multicenter phase I/II study of concurrent chemoradiotherapy. Conclusions: Researchers concluded results suggest that concurrent chemoradiotherapy using MDR- non-related agents and ETP is a promising treatment strategy for localized nasal NK/T-cell…
Cancer
01 Jan 2013
HD Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkin’s Lymphoma
Aim: Prior studies showed that overexpression of bcl-2 and p53 have negative impact on outcome with primary therapy. The study sought to determine if the comprehensive second-line program could overcome these poor prognostic features. Conclusions: Researchers concluded that despite the evidence that p53 and bcl-2 overexpression may predict…
Cancer
01 Jan 2013
The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL)
Aim: To improve progression-free survival (PFS) in MCL using a strategy of incorporating approaches of intensifying induction & intensifying consolidation with high dose chemo radiotherapy (HDT by administering an anthracycline-containing regimen in a dose dense fashion CHOP- or R-CHOP-14) followed by consolidation with ICE HDT/ASCT. Conclusions: Researchers…
Cancer
01 Jan 2013
An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation
Aim: To assess efficacy and toxicity of 2 and 3 drug salvage regimens. Conclusions: Researchers concluded that both VGF and F-GIV can be safely administered on an outpatient basis and show activity against advanced lymphoma Official Title Conditions Study Type Phase II Study Design Patients were stratified into:…
Cancer
01 Jan 2013
Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective, or whether chemotherapy is more effective than observation, in treating pancreatic cancer after surgery. PURPOSE: Phase III trial…
Cancer
01 Jan 2013
IEV and autologous peripheral blood progenitor cell transplant salvage treatment for lymphoid malignancies
Primary endpoints were to confirm the feasibility and efficacy of IEV in poor risk Hodgkin’s lymphoma and aggressive NHLs. Additional endpoints were to try to evaluate its possible role in the salvage strategy of indolent NHLs, lymphoblastic lymphoma and multiple myeloma. Analysis of toxicity and PBSC mobilization. Conclusions…
Cancer
01 Jan 2013
Head and Neck Phase III Iressa Vs Methotrexate Refractory. Iressa Vs Methotrexate (IMEX)
Purpose- This study is to compare ZD1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival. Official Title A Phase III Randomised, Stratified, Parallel-Group, Mulit-Centre, Comparative Study of ZD1839 (Iressa) 250 mg and 500 mg Versus Methotraxate for Previously Treated Patients with Squamous Cell…
Cancer
01 Jan 2013
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
Rationale: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer. Purpose: This randomized…
Cancer
01 Jan 2013
Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
The purpose of this study is to determine whether treatment with etoposide, doxorubicin, cisplatin and mitotane (EDP/M) prolongs survival as compared to streptozotocin and mitotane (Sz/M) in patients with advanced adrenocortical carcinoma (ACC) whose disease is not amenable to complete surgical resection. The Firm-ACT trial is the first ever conducted…
